Market Overview

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Related LGND
UPDATE: Avion Pharma Reports Signing of Commercial License Deal with Ligand Pharma for Development, Commercialization of Four Captisol-Enabled Programs, Ligand Entitled to Upfront Payment
Stocks To Watch For August 12, 2014
Related GSK
GSK Receives FDA Approval Of An Additional Promacta (eltrombopag) Indication For Use In Patients With Severe Aplastic Anaemia
UPDATE: GlaxoSmithKline Receives FDA Approval For Arnuity Ellipta In US For Treatment Of Asthma
Bayer Buys Merck Consumer Care Unit (Fox Business)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. PROMACTA in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.

Posted-In: News FDA

 

Related Articles (LGND + GSK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters